REGENXBIO Investors Face Critical April 14 Deadline in Gene Therapy Securities Class Action

Rosen Law Firm, a leading securities litigation firm, is issuing a final call to REGENXBIO, Inc. ($RGNX) shareholders who suffered significant losses to join a pending class action lawsuit before the rapidly approaching April 14, 2026 deadline. The litigation targets what plaintiffs allege was a systematic pattern of false and misleading statements regarding the efficacy and safety profile of the company's experimental RGX-111 gene therapy, a case with potentially far-reaching implications for how biotechnology companies communicate clinical trial results to investors.

The class action encompasses investors who purchased REGENXBIO securities during the period spanning February 9, 2022 through January 27, 2026—a nearly four-year window that captures the company's major public communications about its lead therapeutic candidate. The lawsuit centers on allegations that REGENXBIO presented materially misleading and overly optimistic assessments of RGX-111's clinical development, while concealing or downplaying safety and efficacy concerns that would later emerge, causing substantial shareholder losses.

The Legal Claims and Allegations

At the heart of the litigation lies a fundamental claim: that REGENXBIO management knowingly or recklessly made false statements about its flagship gene therapy program while simultaneously providing what the complaint characterizes as "overwhelmingly positive public assertions" that diverged significantly from the actual clinical and safety data the company possessed.

Key allegations include:

• Misrepresentations regarding RGX-111 efficacy: Claims that the company overstated the therapeutic effectiveness of its gene therapy candidate in public statements and investor communications
• Safety profile concealment: Allegations that REGENXBIO downplayed or failed to adequately disclose safety concerns identified during clinical development
• Divergence between private and public communications: Suggestions that internal communications differed materially from public disclosures to investors
• Damages spanning nearly four years: The extended class period from early 2022 through January 2026 suggests the alleged misstatements persisted across multiple earnings cycles and corporate announcements

The allegations specifically target the gap between what REGENXBIO told investors publicly about RGX-111 and what the clinical data actually demonstrated regarding the gene therapy's real-world performance and safety characteristics.

Market Context: Gene Therapy Sector Under Scrutiny

The REGENXBIO litigation arrives amid broader industry scrutiny of how gene therapy companies, which operate at the frontier of biomedical innovation, communicate clinical progress to capital markets. The gene therapy sector has experienced significant volatility in recent years, driven by unexpected clinical trial results, regulatory setbacks, and investor recalibration of risk-reward profiles.

Several factors contextualize this case:

• Gene therapy is inherently high-risk: These therapies target previously untreatable genetic diseases but carry elevated safety and efficacy uncertainties compared to traditional drug development
• Investor enthusiasm has cooled: After initial exuberance around gene therapy platforms, investors have become more skeptical and demanding of rigorous clinical evidence
• Regulatory scrutiny is intensifying: The FDA has signaled heightened review of gene therapy safety data, particularly concerning durability claims and long-term patient outcomes
• Historical precedent: Prior securities litigation against biotech companies has centered on similar allegations of optimistic public statements disconnected from underlying clinical realities

For a company like REGENXBIO, which positions gene therapy as its core value driver, misstatements about RGX-111—its lead candidate—would strike at the fundamental basis of investor valuation and stock performance. The nearly four-year class period suggests investors experienced significant declines in share value as more complete information about the program materialized.

Investor Implications and Damages Calculations

The Rosen Law Firm's emphasis on investors with losses exceeding $100,000 underscores the material scale of shareholder harm this litigation addresses. In biotech litigation, damage calculations typically hinge on the difference between what investors paid for shares during the class period and the lower price once the truth about allegedly misleading statements became public.

Key considerations for potential class members:

• Statute of limitations urgency: The April 14, 2026 deadline is a hard cutoff for joining the class action; investors who miss this date will almost certainly be barred from recovery
• No upfront costs: Class action members typically pay nothing unless and until the case succeeds through settlement or judgment
• Proof of purchase requirements: Class members must have purchased REGENXBIO securities during the February 9, 2022–January 27, 2026 window and held shares at some point during this period
• Recovery uncertain but material: If successful, settlements in biotech securities litigation have ranged from single-digit millions to nine-figure recoveries, depending on the strength of evidence and defendant's resources

For investors who suffered significant losses, the class action may represent the primary avenue for recovering damages. Individual lawsuits against REGENXBIO would be prohibitively expensive and face significant litigation hurdles that aggregated class actions circumvent.

Why This Matters for Market Participants

The REGENXBIO case carries implications extending beyond individual shareholders. For the biotechnology sector broadly, the litigation underscores how aggressively plaintiffs' attorneys and investors scrutinize biotech companies' clinical communications. Management teams at $RGNX and peer companies ($ETSY, other gene therapy developers) must carefully calibrate how they present clinical data to avoid the perception that public statements exceed underlying evidence.

For the broader investment community, this case serves as a reminder that gene therapy companies—despite their therapeutic promise—remain subject to the same disclosure standards and fraud prohibitions as conventional pharmaceutical firms. Investors evaluating gene therapy investments must independently verify clinical claims rather than accepting management's characterization at face value.

Looking Forward

With the April 14, 2026 deadline now imminent, affected REGENXBIO shareholders must act decisively. Rosen Law Firm and other plaintiff counsel will likely begin sending final deadline notices to potential class members in coming weeks. For investors who experienced substantial losses from $RGNX holdings between early 2022 and January 2026, consulting with securities counsel about class action participation represents prudent financial stewardship.

The litigation's ultimate resolution—whether through settlement negotiations, judgment, or dismissal—will likely take years to unfold. However, the deadline to preserve one's right to participate is fixed and inescapable. Investors holding documentation of their REGENXBIO purchases during the class period would be well-advised to review their holding statements and consider engaging legal counsel before this critical deadline passes.